Akari Therapeutics (AKTX) Cash from Investing Activities (2014 - 2016)

Akari Therapeutics has disclosed Cash from Investing Activities across 3 years of filings, most recently posting -$42083.0 for Q1 2016.

• Cash from Investing Activities for Q1 2016 came in at -$42083.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2016 was $1.3 million (changed N/A YoY), and the FY2024 annual result was $382000.0, changed N/A from the prior year.
• Cash from Investing Activities came in at -$42083.0 for Q1 2016 at Akari Therapeutics, down from -$18779.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $1.4 million in Q3 2015 to a low of -$142000.0 in Q2 2014.
• The 3-year median for Cash from Investing Activities is -$18779.0 (2015), against an average of $269943.0.
• Peak annual rise in Cash from Investing Activities reached 893.36% in 2015, while the deepest fall reached 893.36% in 2015.
• Akari Therapeutics' Cash from Investing Activities stood at $142000.0 in 2014, then plunged by 113.22% to -$18779.0 in 2015, then sank by 124.1% to -$42083.0 in 2016.
• The last three Cash from Investing Activities figures came in at -$42083.0 (Q1 2016), -$18779.0 (Q4 2015), and $1.4 million (Q3 2015), per Business Quant data.